CQP 201‐403 in Parkinson's disease: An open‐label pilot study

Ronald F. Pfeiffer, Leonel H. Herrera, Carolyn S. Glaeske, Ruth E. Hofman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The dopamine agonist, CQP 201–403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201‐403 may be of value in the treatment of Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalMovement Disorders
Issue number3
StatePublished - 1989
Externally publishedYes


  • CQP 201‐403
  • Dopamine agonist
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'CQP 201‐403 in Parkinson's disease: An open‐label pilot study'. Together they form a unique fingerprint.

Cite this